Comparative Pharmacology
Head-to-head clinical analysis: CYLTEZO versus YUFLYMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYLTEZO versus YUFLYMA.
CYLTEZO vs YUFLYMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Tumor necrosis factor (TNF) alpha blocker; a monoclonal antibody that binds to soluble and membrane-bound TNF-alpha, inhibiting its interaction with TNF receptors and reducing inflammatory responses.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
None Documented
None Documented
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Terminal elimination half-life approximately 10-20 days (mean 14 days), supporting every-other-week dosing intervals.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Adalimumab is primarily degraded into small peptides and amino acids via catabolic pathways; renal excretion of intact antibody is negligible. No biliary or fecal elimination data available.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor